It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DNLI’s FA Score shows that 0 FA rating(s) are green whileINCY’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DNLI’s TA Score shows that 3 TA indicator(s) are bullish while INCY’s TA Score has 5 bullish TA indicator(s).
DNLI (@Biotechnology) experienced а -3.53% price change this week, while INCY (@Biotechnology) price change was +2.79% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +3.00%. For the same industry, the average monthly price growth was +5.57%, and the average quarterly price growth was -1.69%.
DNLI is expected to report earnings on Jul 31, 2025.
INCY is expected to report earnings on Aug 05, 2025.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
DNLI | INCY | DNLI / INCY | |
Capitalization | 1.98B | 12.5B | 16% |
EBITDA | -505.16M | 407M | -124% |
Gain YTD | -32.974 | -6.602 | 499% |
P/E Ratio | N/A | 322.55 | - |
Revenue | 0 | 4.41B | - |
Total Cash | 818M | 2.41B | 34% |
Total Debt | 48.6M | 43.1M | 113% |
DNLI | INCY | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 75 | 19 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 93 Overvalued | 92 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 40 | 89 | |
PRICE GROWTH RATING 1..100 | 64 | 50 | |
P/E GROWTH RATING 1..100 | 98 | 1 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
INCY's Valuation (92) in the Biotechnology industry is in the same range as DNLI (93). This means that INCY’s stock grew similarly to DNLI’s over the last 12 months.
INCY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DNLI (100). This means that INCY’s stock grew similarly to DNLI’s over the last 12 months.
DNLI's SMR Rating (40) in the Biotechnology industry is somewhat better than the same rating for INCY (89). This means that DNLI’s stock grew somewhat faster than INCY’s over the last 12 months.
INCY's Price Growth Rating (50) in the Biotechnology industry is in the same range as DNLI (64). This means that INCY’s stock grew similarly to DNLI’s over the last 12 months.
INCY's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for DNLI (98). This means that INCY’s stock grew significantly faster than DNLI’s over the last 12 months.
DNLI | INCY | |
---|---|---|
RSI ODDS (%) | 1 day ago90% | 1 day ago65% |
Stochastic ODDS (%) | 1 day ago82% | 1 day ago72% |
Momentum ODDS (%) | 1 day ago86% | 1 day ago60% |
MACD ODDS (%) | 1 day ago86% | N/A |
TrendWeek ODDS (%) | 1 day ago83% | 1 day ago62% |
TrendMonth ODDS (%) | 1 day ago85% | 1 day ago58% |
Advances ODDS (%) | 4 days ago78% | 4 days ago59% |
Declines ODDS (%) | 1 day ago80% | 1 day ago63% |
BollingerBands ODDS (%) | 1 day ago81% | 1 day ago61% |
Aroon ODDS (%) | 1 day ago70% | 1 day ago61% |
A.I.dvisor indicates that over the last year, INCY has been loosely correlated with REGN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if INCY jumps, then REGN could also see price increases.
Ticker / NAME | Correlation To INCY | 1D Price Change % | ||
---|---|---|---|---|
INCY | 100% | -0.42% | ||
REGN - INCY | 43% Loosely correlated | -1.29% | ||
AXON - INCY | 39% Loosely correlated | N/A | ||
TECH - INCY | 37% Loosely correlated | N/A | ||
LGND - INCY | 36% Loosely correlated | N/A | ||
ZYME - INCY | 35% Loosely correlated | -3.85% | ||
More |